BR112013017416A2 - derivado de indola ou indazola ou sal do mesmo - Google Patents

derivado de indola ou indazola ou sal do mesmo

Info

Publication number
BR112013017416A2
BR112013017416A2 BR112013017416A BR112013017416A BR112013017416A2 BR 112013017416 A2 BR112013017416 A2 BR 112013017416A2 BR 112013017416 A BR112013017416 A BR 112013017416A BR 112013017416 A BR112013017416 A BR 112013017416A BR 112013017416 A2 BR112013017416 A2 BR 112013017416A2
Authority
BR
Brazil
Prior art keywords
represent
hydrogen atom
salt
optionally substituted
carbon atoms
Prior art date
Application number
BR112013017416A
Other languages
English (en)
Inventor
Yoshimura Chihoko
Kitade Makoto
Ohkubo Shuichi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BR112013017416A2 publication Critical patent/BR112013017416A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivado de indola ou indazola ou sal do mesmo a presente invenção se refere a provisão de um novo composto de indazola que é capaz de inibir hsp90 e mostra um efeito citostático em células de câncer. a presente invenção se refere a provisão de um fármaco útil para evitar e/ou tratar, com base em um efeito inibitório de hsp90, uma doença em que hsp90 participa, em particular, câncer. um composto representado pela fórmula geral (i) ou um sal do mesmo: em que x representa ch ou n; qualquer um ou dois de y^ 1^, y^ 2^, y^ 3^ e y^ 4^ representa c-r^ 3^ ou n, e os outros representam ch; a e b são os mesmos ou diferentes e representam um grupo heterocíclico não saturado monocíclico opcionalmente substituído dotado de 1 a 4 heteroátomos selecionados a partir de n, s e o; r^ 1^ representa um átomo de hidrogênio, um grupo alquila opcionalmente substituído dotado de 1 a 6 átomos de carbono etc.; r^ 2^ representa um átomo de hidrogênio, um átomo de halogênio etc.; r^ 3^ representa um átomo de hidrogênio, um átomo de halogênio etc.; r^ 4^ e r^ 5^ são os mesmos ou diferentes e representam um grupo hidroxila etc.; r^ 6^ e r^ 7^ são os mesmos ou diferentes e representam um átomo de hidrogênio, um grupo alquila dotado de 1 a 6 átomos de carbono.; e r^ 8^ representa um grupo cicloalquila opcionalmente substituído dotado de 3 a 7 átomos de carbono etc.
BR112013017416A 2011-01-07 2012-01-06 derivado de indola ou indazola ou sal do mesmo BR112013017416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011002147 2011-01-07
PCT/JP2012/050140 WO2012093707A1 (ja) 2011-01-07 2012-01-06 新規インドール、インダゾール誘導体又はその塩

Publications (1)

Publication Number Publication Date
BR112013017416A2 true BR112013017416A2 (pt) 2019-09-24

Family

ID=46457557

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017416A BR112013017416A2 (pt) 2011-01-07 2012-01-06 derivado de indola ou indazola ou sal do mesmo

Country Status (14)

Country Link
US (1) US9120780B2 (pt)
EP (1) EP2662367B1 (pt)
JP (1) JP5865844B2 (pt)
KR (1) KR20140025326A (pt)
CN (1) CN103402995B (pt)
AU (1) AU2012204650A1 (pt)
BR (1) BR112013017416A2 (pt)
CA (1) CA2834101A1 (pt)
ES (1) ES2589557T3 (pt)
HK (1) HK1189384A1 (pt)
MX (1) MX2013007937A (pt)
RU (1) RU2013136861A (pt)
TW (1) TW201309672A (pt)
WO (1) WO2012093707A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013999B1 (pt) 2009-07-10 2020-06-02 Taiho Pharmaceutical Co., Ltd. Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer
CN105793421A (zh) * 2013-10-02 2016-07-20 大鹏药品工业株式会社 耐性突变型90kDa热休克蛋白质
CN104744459A (zh) * 2013-12-27 2015-07-01 中国药科大学 吡啶并吡啶酮及其衍生物的合成方法
DE102014106987A1 (de) * 2014-02-14 2015-08-20 Hartmut Yersin Organische TADF-Moleküle mit sterischer Behinderung am Donator und am Akzeptor für opto-elektronische Vorrichtungen
DE102014106986B4 (de) * 2014-02-14 2023-10-12 Samsung Display Co., Ltd. Organische Moleküle mit kleinen Triplett-Singulett-Energieabständen für eine effektive verzögerte Fluoreszenz zur Anwendung in opto-elektronischen Vorrichtungen
CN117003754A (zh) * 2022-04-28 2023-11-07 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203068A (en) 1981-06-08 1982-12-13 Teikoku Hormone Mfg Co Ltd Novel 1-phenylisoquinoline derivative
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
MX2008003202A (es) * 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
RS53446B (en) * 2006-05-25 2014-12-31 Synta Pharmaceuticals Corp. TRIAZOLE UNITS MODULATING HSP90 ACTIVITY
WO2008024978A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008026704A1 (fr) 2006-08-31 2008-03-06 Kyowa Hakko Kogyo Co., Ltd. Dérivé d'isoquinoline
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2229381A1 (en) * 2007-12-06 2010-09-22 Schering Corporation Gamma secretase modulators
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
AR075874A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion
BRPI1013999B1 (pt) 2009-07-10 2020-06-02 Taiho Pharmaceutical Co., Ltd. Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer

Also Published As

Publication number Publication date
MX2013007937A (es) 2013-11-01
AU2012204650A1 (en) 2013-08-01
EP2662367A4 (en) 2014-06-25
WO2012093707A1 (ja) 2012-07-12
EP2662367A1 (en) 2013-11-13
HK1189384A1 (zh) 2014-06-06
RU2013136861A (ru) 2015-02-20
TW201309672A (zh) 2013-03-01
US9120780B2 (en) 2015-09-01
CN103402995A (zh) 2013-11-20
CN103402995B (zh) 2016-08-31
EP2662367B1 (en) 2016-08-17
ES2589557T3 (es) 2016-11-15
CA2834101A1 (en) 2012-07-12
US20130289072A1 (en) 2013-10-31
JP5865844B2 (ja) 2016-02-17
JPWO2012093707A1 (ja) 2014-06-09
KR20140025326A (ko) 2014-03-04

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
BR112013017416A2 (pt) derivado de indola ou indazola ou sal do mesmo
BR112013017520A2 (pt) composto bicíclico ou sal do mesmo
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
EA201290260A1 (ru) Бензимидазол-имидазольные производные
BR112017017529A2 (pt) derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
BR112015019790A2 (pt) derivado de piridina monocíclica
MY169179A (en) Novel piperidine compound or salt thereof
AR080969A1 (es) Compuesto biciclico
CO2018010787A2 (es) Compuesto de griseofulvina
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
BR112015021768A2 (pt) inibidores do vírus da hepatite c
BR112018003489A2 (pt) n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
BR112016009811A2 (pt) derivado de carboximetil piperidina
UA87284C2 (ru) Соединения фенилпиридилпиперазина, способ их получения и фармацевтическая композиция, которая их содержит
BR112013005823A2 (pt) compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonima, norefnefrina ou dopamina
BR112012014196A2 (pt) agente para prevenir ou melhorar a pigmentação
CO6300944A2 (es) Derivado de hidroxi-quinoxalin-carboxamida
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
BR112014016197A8 (pt) derivado de paroxetina
CO6190551A2 (es) Derivado de alquilsulfona
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112018000925A2 (pt) composto heterocíclico contendo nitrogênio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.